|
|
News Breaks | | | | January 28, 2013 | | 07:05 EDT |  | SPPI | Spectrum presents Belinostat safety profile at T-Cell Lymphoma Forum
Spectrum Pharmaceuticals announced safety findings from the pivotal, registrational Phase 2 BELIEF trial of belinostat, a pan-histone deacetylase inhibitor. As featured in an oral presentation at the T-Cell Lymphoma Forum held in San Francisco, January 24-26, the BELIEF trial safety evaluation showed belinostat had an acceptable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma, including patients who have received a previous allogeneic or autologous stem cell transplant. The BELIEF trial is evaluating the efficacy and safety of intravenous belinostat for the treatment of patients with R/R PTCL. As announced in December 2012, the BELIEF trial surpassed an objective response rate of at least 20% in these patients, the study’s primary efficacy endpoint as established under a Special Protocol Assessment agreement with the FDA. | |
|
News For SPPI From The Last 14 Days Check below for free stories on SPPI the last two weeks. |
|
|
| May 15, 2013 | | 19:34 EDT | | SPPI | On The Fly: After Hours Movers
 Subscribe for More Information | | | 11:16 EDT |  | SPPI | Options with decreasing implied volatility: RAX CSC SPPI MBI PANL
| | | May 9, 2013 | | 07:09 EDT |  | SPPI | Spectrum reports Q1 EPS (5c), consensus (16c)
Reports Q1 revenue $38.7M, consensus $36.42M. Says pivotal data in relapsed/refractory peripheral T-cell lymphoma from late-stage drug Belinostat to be presented as an oral presentation at ASCO 2013; the company expects to submit an NDA this summer. Company expects enrollment in the Captisol-enabled melphalan study in multiple myeloma to be completed in 2013, with NDA submission in 2014. | |
|
|
|
|
|
|
